Advertisement

Inhibitors of Prostaglandin Synthesis in Cancer Chemoprevention

  • B. S. Reddy
Part of the Developments in Oncology book series (DION, volume 71)

Abstract

Chemoprevention which focuses on the inhibition of carcinogenesis by chemical agents, both synthetic and naturally occurring, is a concept that these substances could inhibit partially or totally the development of neoplasms. Several naturally-occurring substances and synthetic chemicals have been intensely investigated for their chemopreventive action on chemically-induced neoplasms of various organ sites (1) Arachidonic acid, a precursor of several biologically active prostaglandins (PGs), is the most abundant polyenoic fatty acid found in the phospholipids of mammalian tissues. A number of experimental animal tumors and human cancers have been shown to contain and/or produce large quantities of PGs, particularly those of E series (2). PGs have been shown to significantly affect cell proliferation and tumor growth in a variety of experimental situations. Therefore, the possibility exists that the modulation of production of PGs may influence the tumorigenesis. This paper reviews the relationship between the inhibitors of PG synthesis and cancer prevention with special reference to cancer of the colon.

Keywords

Colon Carcinogenesis Carcinogen Treatment Induce Colon Carcinogenesis American Health Foundation Colon Tumor Incidence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boon, C.W., Kelloff, G. and Malone, W.E. Cancer Res. 50:29, 1990.Google Scholar
  2. 2.
    Jaffe, B.M. Prostaglandins 6:453–461, 1974.PubMedCrossRefGoogle Scholar
  3. 3.
    Pollard, M. and Luckert, P.H. J. Natl. Cancer Inst. 70:1103–1105, 1983.PubMedGoogle Scholar
  4. 4.
    Kudo, T., Narisawa, T. and Abo, S. Gann. 71:260–264, 1980.PubMedGoogle Scholar
  5. 5.
    Narisawa, T., Sato, M., Tani, M., Kudo, T., Takahashi, T. and Goto, A. Cancer Res. 41:1954–1957, 1981.PubMedGoogle Scholar
  6. 6.
    Pollard, M. and Luckert, P.H. Cancer Lett. 25:117–121, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Reddy, B.S., Maruyama, H. and Kelloff, G. Cancer Res. 47:5340–5346, 1987.PubMedGoogle Scholar
  8. 8.
    Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E. and Kelloff, G. Cancer Res. 50:2562–2568, 1990.PubMedGoogle Scholar
  9. 9.
    Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G. and Reddy, B.S. Cancer Res. 51:4528–4534, 1991PubMedGoogle Scholar
  10. 10.
    Reddy, B.S. and Maruyama, H. Cancer Res. 46:3367–3370, 1986.PubMedGoogle Scholar
  11. 11.
    Reddy, B.S. and Sugie, S. Cancer Res. 48: 6642–6647, 1988.PubMedGoogle Scholar
  12. 12.
    Hirosa, M., Masuda, A., Ito, N., Kamano, K. and Okuyama, H. Carcinogenesis 11:731–735, 1990.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • B. S. Reddy
    • 1
  1. 1.Division of Nutritional CarcinogenesisAmerican Health FoundationValhallaUSA

Personalised recommendations